Published On: Wed, Oct 19th, 2016

MiMedx Group, Inc (MDXG) Latest Broker Views


A number of investment brokers have recently updated their price targets on shares of MiMedx Group, Inc (MDXG).

Most recent broker ratings

04/27/2016 – MiMedx Group, Inc was downgraded to “equal-weight” by analysts at First Analysis.

04/11/2016 – MiMedx Group, Inc had its “strong buy” rating reiterated by analysts at Needham & Company. They now have a USD 12 price target on the stock.

12/18/2015 – MiMedx Group, Inc had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 12 price target on the stock.

12/17/2015 – MiMedx Group, Inc had its “buy” rating reiterated by analysts at Brean Capital. They now have a USD 12 price target on the stock.

10/30/2015 – MiMedx Group, Inc was upgraded to “outperform” by analysts at Northland Securities. They now have a USD 10 price target on the stock.

05/01/2015 – MiMedx Group, Inc was upgraded to “strong-buy” by analysts at Zacks. They now have a USD 11 price target on the stock.

03/02/2015 – MiMedx Group, Inc had its “” rating reiterated by analysts at Craig-Hallum. They now have a USD 13 price target on the stock.

The share price of MiMedx Group, Inc (MDXG) was up +1.32% during the last day of trading, with a day high of 8.54. 328529 shares were traded during the last session.

The stock’s 50 day moving average is 8.48 and its 200 day moving average is 7.91. The stock’s market capitalization is 926.55M. MiMedx Group, Inc has a 52-week low of 6.64 and a 52-week high of 9.90.

MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.